AN2 Therapeutics Initiates Phase 2 Trial of Epetraborole for Difficult-to-Treat M. abscessus Lung Disease
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies using its proprietary boron chemistry platform, has announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating epetraborole for the treatment of pulmonary disease caused by Mycobacterium abscessus (M. abscessus). This marks an important step forward in addressing a serious and often treatment-resistant lung infection that currently lacks approved therapeutic options.
The newly launched trial is designed to assess the safety, efficacy, and pharmacokinetics of epetraborole, an orally administered investigational drug that inhibits leucyl-tRNA synthetase (LeuRS), a key enzyme essential for bacterial protein synthesis. By targeting this mechanism, epetraborole aims to disrupt bacterial growth in a novel and potentially more effective way compared to existing therapies.
The Phase 2 study will enroll approximately 84 patients and will be conducted across multiple centers in the United States. Structured as a randomized, double-blind clinical trial, the study is expected to take place at an estimated 10 to 15 sites nationwide. Patient screening has already begun, signaling the active progression of the trial, with topline results anticipated in late 2027.
The trial is being led by Dr. Kevin L. Winthrop, a prominent expert in infectious diseases and public health and a professor at Oregon Health & Science University (OHSU). He is collaborating with a network of investigators across participating clinical sites to ensure a comprehensive evaluation of the drug’s potential benefits.
M. abscessus is widely recognized as one of the most challenging pulmonary pathogens to treat. Patients diagnosed with this infection often face a prolonged and burdensome treatment journey involving complex multidrug regimens. These typically include daily intravenous (IV) antibiotics administered over extended periods, often accompanied by significant side effects and variable efficacy. As a result, patient adherence and treatment success rates remain problematic.
Dr. Winthrop emphasized the urgent need for improved therapeutic options. He noted that current treatments are not only difficult to tolerate but also limited in their effectiveness, leaving both patients and healthcare providers with few viable solutions. According to him, an oral therapy like epetraborole, if proven safe and effective, could represent a major advancement in care. Its ease of administration and novel mechanism of action could allow it to serve as a foundational component in combination treatment regimens, potentially simplifying therapy and improving patient outcomes.
Epetraborole’s oral formulation is particularly significant in the context of M. abscessus treatment. Unlike existing therapies that rely heavily on intravenous administration, an oral drug could greatly reduce the logistical and physical burden on patients. This shift could enhance quality of life, increase adherence to treatment protocols, and ultimately lead to better clinical outcomes.
Eric Easom, Co-founder, Chairman, President, and Chief Executive Officer of AN2 Therapeutics, highlighted the importance of this milestone for both the company and the broader patient community. He underscored the significant unmet medical need faced by individuals living with M. abscessus lung disease, describing the condition as serious and lacking any U.S. Food and Drug Administration (FDA)-approved treatments.
Easom expressed confidence in epetraborole’s potential, citing its targeted mechanism and oral dosing as key advantages. He emphasized the company’s commitment to transforming the treatment landscape for this challenging infection by developing therapies that are not only effective but also more accessible and patient-friendly.
The initiation of this investigator-led trial reflects a collaborative approach to drug development, leveraging academic expertise and clinical research networks to advance promising therapies. Such partnerships are often critical in addressing rare or difficult-to-treat diseases, where traditional development pathways may be more complex or resource-intensive.
In addition to evaluating clinical outcomes, the study will also generate important pharmacokinetic data to better understand how the drug behaves in the body. This information will be essential in optimizing dosing strategies and guiding future development efforts.
Patients and healthcare professionals interested in learning more about the study can access detailed information through ClinicalTrials.gov, where the trial is registered under the identifier NCT07301320. The listing provides comprehensive details about eligibility criteria, study design, and participating locations.
M. abscessus complex lung disease is a type of nontuberculous mycobacterial (NTM) infection that primarily affects individuals with underlying lung conditions or weakened immune systems. The bacteria are commonly found in the environment, including water and soil, and can cause severe and persistent respiratory symptoms once established in the lungs.
The disease is particularly difficult to manage due to the organism’s intrinsic resistance to many commonly used antibiotics. This resistance necessitates the use of combination therapies, often involving multiple drugs with varying mechanisms of action. Even with aggressive treatment, outcomes can be inconsistent, and relapse rates are relatively high.
Given these challenges, the development of new therapies with novel mechanisms is considered essential. Epetraborole’s ability to target leucyl-tRNA synthetase represents a different approach compared to traditional antibiotics, potentially offering a way to overcome existing resistance patterns.
The broader implications of this trial extend beyond a single drug candidate. Success in this area could pave the way for further innovation in the treatment of NTM infections and other difficult bacterial diseases. It also highlights the growing importance of targeted therapies that address specific biological pathways, rather than relying solely on broad-spectrum antimicrobial approaches.
As the trial progresses, the medical community will be closely watching for early signals of efficacy and safety. Positive results could lead to larger, more definitive studies and eventually regulatory submissions, bringing the field one step closer to a much-needed approved therapy.
For patients living with M. abscessus lung disease, the initiation of this trial represents a hopeful development. While challenges remain, the advancement of epetraborole into Phase 2 testing signals meaningful progress in the search for more effective, tolerable, and accessible treatment options.
In summary, AN2 Therapeutics’ launch of this Phase 2 investigator-initiated trial marks a significant milestone in the fight against M. abscessus lung disease. By combining scientific innovation, clinical expertise, and a patient-centered approach, the study aims to address a critical gap in current treatment options and improve outcomes for individuals affected by this debilitating condition.
About M. abscessus Complex Lung Disease
M. abscessus lung disease is a rapidly growing nontuberculous mycobacterium associated with chronic, progressive lung disease that can lead to significant morbidity and mortality. Current treatment typically involves prolonged, multidrug regimens that may be poorly tolerated and have variable success, underscoring the urgent need for new, targeted therapies.
About Epetraborole
Epetraborole is a novel, orally administered, once daily, small molecule inhibitor of leucyl tRNA synthetase (LeuRS), designed to disrupt bacterial protein synthesis. Epetraborole is being developed to address significant unmet medical needs in various therapeutic areas, including difficult-to-treat mycobacterial infections.
About AN2 Therapeutics
AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to be active in 2026, two preclinical candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.
